SCHEMBL6499080

SCHEMBL6499080

OC(Cc1ccccc1)c1ccc2c(c1)c(-c1ccc(F)cc1)nn2C1CCCO1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.39
CNR1 P21554 2/20 0.38
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
OXTR P30559 1/20 0.35
AVPR1A P37288 1/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
EGFR P00533 1/20 0.34
BTK Q06187 1/20 0.34
CMKLR1 Q99788 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5372891 0.97 CNR1 (0.39) POLBCNR1RXRARXRBRXRG
SCHEMBL5802483 0.81 RXRA (0.42) POLBRXRARXRBRXRGEGFR
SCHEMBL5374585 0.76 RXRA (0.36) POLBRXRARXRBRXRGMERTK
SCHEMBL5388444 0.76 RXRA (0.36) POLBRXRARXRBRXRGMAPT
SCHEMBL5374578 0.76 RXRA (0.36) POLBRXRARXRBRXRGMERTK
SCHEMBL5372228 0.74 CYP4F2 (0.38) POLBRXRARXRBRXRGALDH1A1
SCHEMBL7170915 0.74 RXRA (0.40) POLBCNR1RXRARXRBRXRG
SCHEMBL5375255 0.73 KDM4E (0.42) POLBCNR1RXRARXRBRXRG
SCHEMBL5374599 0.72 RXRA (0.39) POLBRXRARXRBRXRGALDH1A1
SCHEMBL5374603 0.72 RXRA (0.39) POLBRXRARXRBRXRGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897231-B2 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, INC. (US) 2005-05-24 US disclosed
US-20020103229-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, LLC 2002-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103229-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto MAP3K7, MAP3K1, MAP3K8 POLB 3399/4885CNR1 1508/4885RXRA 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.